Roquefort Therapeutics (ROQ) Share Price, News & Analysis

Company Overview

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.

Key Stats

• Today's Range: 3.80 to 4.08
• 50-Day Range: 3.50 to 6.50
• 52-Week Range: 3.30 to 9.50
• Volume: 520,577 shs
• Average Volume: 602,056 shs
• Market Capitalization: £5.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ROQ Stock Analysis - Frequently Asked Questions

How have ROQ shares performed this year?

Roquefort Therapeutics' stock was trading at GBX 7.25 at the beginning of 2024. Since then, ROQ shares have decreased by 45.9% and is now trading at GBX 3.92.
View the best growth stocks for 2024 here.

How do I buy shares of Roquefort Therapeutics?

Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Roquefort Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Roquefort Therapeutics investors own include Vislink Technologies (XGTI), AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX) and Abacus Health Products (ABAHF).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:ROQ
• CUSIP: N/A
• CIK: N/A
• Web: www.roquefortinvest.com
• Phone: 44 20 3290 9339
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -27.05%
• Return on Assets: -15.86%

Debt

• Debt-to-Equity Ratio: 12.37
• Current Ratio: 0.79
• Quick Ratio: 3.07

Sales & Book Value

• Annual Sales: £637.00
• Price / Sales: 7,953.77
• Cash Flow: GBX 2.62 per share
• Price / Cash Flow: 1.49
• Book Value: GBX 4 per share
• Price / Book: 0.98

Miscellaneous

• Outstanding Shares: 129,150,000
• Free Float: N/A
• Market Cap: £5.07 million
• Optionable: Not Optionable
• Beta: 0.05